Xtant Medical Holdings, Inc.(XTNT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,602 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in XTNT
Events flagged as statistical outliers against XTNT's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-16
XTNT quality score dropped 27 points (52→25) on a new filing
View source filing →
XTNT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Xtant Medical Holdings, Inc. (XTNT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XTNT at 26.9/100 on a 32-signal composite quality model, placing it at rank #2,602 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (15.2) and revenue scale (17.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xtant Medical Holdings, Inc. reports quarterly revenue of $23.0M, net income of $-9.4M, free cash flow of $-7.6M. Top institutional holders of XTNT by reported 13-F value include Nantahala Capital Management, AWM Investment Company, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XTNT trades on the NYSE exchange and files with the SEC under CIK 1453593. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XTNT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xtant Medical Holdings, Inc. directly from SEC EDGAR. Xtant Medical Holdings, Inc.'s 13F Pro composite quality score has ranged between 23 and 65 since 2026, currently 26.9 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$23.0M
Net Income
Q2 2026
$-9.4M
Free Cash Flow
Q2 2026
$-7.6M
ROIC
Q2 2026
-71.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+14.2% YoYNet Income
+130.2% YoYOperating Income
+160.3% YoYEPS (Diluted)
+125.0% YoYTotal Assets
+0.3% YoYTotal Debt
-34.1% YoYOp. Cash Flow
+205.5% YoYFree Cash Flow
+163.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $133.9M +14.2% | $117.3M +28.4% | $91.3M +57.5% | $58.0M +4.9% | $55.3M +3.6% | $53.3M |
| Net Income | $5.0M +130.2% | $-16.4M -2592.3% | $660.0K +107.8% | $-8.5M -75.0% | $-4.8M +31.0% | $-7.0M |
| Operating Income | $7.3M +160.3% | $-12.1M -18.9% | $-10.2M -50.4% | $-6.8M -75.3% | $-3.9M -413.2% | $-751.0K |
| EPS (Diluted) | $0.03 +125.0% | $-0.12 -1300.0% | $0.01 +111.1% | $-0.09 -50.0% | $-0.06 +76.0% | $-0.25 |
| Total Assets | $94.1M +0.3% | $93.8M +1.3% | $92.6M +53.8% | $60.2M +10.1% | $54.7M +31.9% | $41.5M |
| Total Debt | $14.5M -34.1% | $22.0M +28.4% | $17.2M +42.8% | $12.0M +2.0% | $11.8M -29.8% | $16.8M |
| Operating Cash Flow | $12.5M +205.5% | $-11.9M -25.0% | $-9.5M -78.2% | $-5.3M -1316.6% | $439.0K +160.1% | $-731.0K |
| Free Cash Flow | $10.2M +163.5% | $-16.0M -45.9% | $-11.0M -54.4% | $-7.1M -323.9% | $-1.7M +26.4% | $-2.3M |
Get alerted when XTNT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Xtant Medical Holdings, Inc. including:
Top Institutional Holders of XTNT
Nantahala Capital Management, LLC
$28.8M68,394,000 shAWM Investment Company, Inc.
$2.5M5,976,910 shVANGUARD CAPITAL MANAGEMENT LLC
$848.1K2,014,603 shRENAISSANCE TECHNOLOGIES LLC
$393.7K935,119 shGEODE CAPITAL MANAGEMENT, LLC
$217.8K517,133 shCrescent Grove Advisors, LLC
$173.5K412,024 shNANO CAP NEW MILLENNIUM GROWTH FUND L P
$168.4K400,000 shVANGUARD FIDUCIARY TRUST CO
$108.6K257,988 shCITADEL ADVISORS LLC
$80.6K191,369 shACADIAN ASSET MANAGEMENT LLC
$73.0K180,299 sh
| Fund | Value | Shares |
|---|---|---|
| Nantahala Capital Management, LLC | $28.8M | 68,394,000 |
| AWM Investment Company, Inc. | $2.5M | 5,976,910 |
| VANGUARD CAPITAL MANAGEMENT LLC | $848.1K | 2,014,603 |
| RENAISSANCE TECHNOLOGIES LLC | $393.7K | 935,119 |
| GEODE CAPITAL MANAGEMENT, LLC | $217.8K | 517,133 |
| Crescent Grove Advisors, LLC | $173.5K | 412,024 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $168.4K | 400,000 |
| VANGUARD FIDUCIARY TRUST CO | $108.6K | 257,988 |
| CITADEL ADVISORS LLC | $80.6K | 191,369 |
| ACADIAN ASSET MANAGEMENT LLC | $73.0K | 180,299 |
Companies Similar to XTNT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
DarioHealth Corp.
ASCENT INDUSTRIES CO.
NATURAL ALTERNATIVES INTERNATIONAL INC
EXAGEN INC.
Pulmonx Corp
ADC Therapeutics SA
System1, Inc.
CHAMPIONS ONCOLOGY, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put XTNT on your watchlist
Track score changes the day Xtant Medical Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is XTNT a good stock to buy?
13F Pro's AI-powered analysis of Xtant Medical Holdings, Inc. (XTNT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XTNT are available on the XTNT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XTNT is classified as a small company.
Which hedge funds own XTNT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XTNT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xtant Medical Holdings, Inc.'s investment landscape.